White Paper: Anatomy of a failure to launch: A review of barriers to generic and biosimilar market entry and the use of competition law as a remedy

(more…)

Educational material on biosimilar medicines, developed by IGBA (International Generic and Biosimilar Medicines Association)

(more…)

(more…)

Positioning Statements on Physician-led Switching for Biosimilar Medicines


Positioning statements on physician-led switching for biosimilar medicines (September 2020)


Biosimilar medicines group position on physician-led switching (July 2015)


Biosimilar medicines group position on biologic pharmacy substitution (September 2020)

Second wave pandemic preparedness: procurement principles

Policy Roadmap for Medicines Manufacturing Leadership

Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns

Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney

LESSONS LEARNED FROM COVID-19 – POLICY PAPER

Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic

Position Paper. Incentives Review The Orphan and Paediatric Incentives